// App-Quantinova.ai

836 : The Plasma Cell Transcription Factor XBP1 is Required To Mitigate The Unfolded Protein Response In Ph+ ALL

Researchers

Presenter

  • Behzad Kharabi Masouleh

Principal Investigators

  • Huimin Geng

  • Christian Hurtz

  • Markus Muschen

  • Chuanxin Huang

  • Lai N Chan

  • Srividya Swaminathan

  • Haibo Sun

  • H. Phillip Koeffler

  • Ari Melnick

  • Elisabeth Paietta

  • Laurie H. Glimcher

Medical Centers

  • UCLA School of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA

  • Provost for Medical Affairs, Weill Cornell Medical College, New York, NY

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • Department of Medicine/Hematology-Oncology and Department of Pharmacology, Weill Cornell Medical College, New York, NY

  • Department of Pharmacology, Weill Cornell Medical College, New York, NY

  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA

  • Department of Neurology, Albert Einstein College of Medicine, Bronx, NY

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Acute lymphoblastic leukemia

  • Multiple Myeloma

  • Lung disease, immunodeficiency, and chromosome breakage syndrome

Biomarkers

  • Nucleoside diphosphate kinase A

  • p53

  • c-Jun N-terminal kinase

  • DNA Damage Inducible Transcript 3

  • Interleukin-7

  • Signal transducer and activator of transcription 5

  • White Blood Cell

  • X-Box Binding Protein 1

Drug/Treatment

  • Tamoxifen

  • Afimoxifene

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved